



Docket No. PRD-2008-USPCT1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Peeters et al.

Art Unit: Unassigned

App'n. No.: 10/532,740 ✓

Examiner: Unassigned

Filed : April 26, 2005

For : GENES WHOSE EXPRESSION IS INCREASED IN RESPONSE TO
STIMULATION BY CORTICOTROPIN-RELEASING HORMONE

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September 29, 2006

(Date of Deposit)

Laura A. Donnelly

(Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/

(Signature)

September 29 2006

(Date of Signature)

MAIL STOP DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure
Statement mailed on April 26, 2005.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above
identified application is hereby disclosed. Inclusion of
information in this statement is not to be construed as an
admission that this information is material as that term is
defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of §180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).



☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD-2008-USPCT1/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

Laura A. Donnelly
Reg. No. 38,435
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729
DATED: September 29, 2006

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/532,740
Filing Date	April 26, 2005
First Named Inventor	Pieter Johan Peeters
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	PRD-2008-USPCT1

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Christine Saoud/	Date Considered	04/14/2008
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for

PTC/SB08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/532,740
Filing Date	April 26, 2005
First Named Inventor	Pieter Johan Peeters
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	PRD-2008-USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		De Souza, E., "Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role in Central Nervous System and Immune Disorders", <i>Psychoneuroendocrinology</i> , Vol. 20, No. 8, pp. 789-819 (1995).	
		Holsboer, F., "Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy", <i>Journal of Affective Disorders</i> , Vol. 62, pp. 77-91 (2001).	
		Holsboer, F. et al., "Blunted Aldosterone and ACTH Release After Human CRH Administration in Depressed Patients", <i>Am. J. Psychiatry</i> , Vol. 144, No. 2, pp. 229-231 (1987).	
		Holsboer, F. et al., "Human Corticotropin-Releasing Hormone in Depression - Correlation with Thyrotropin Secretion following Thyrotropin-Releasing Hormone", <i>Biol. Psychiatry</i> , Vol. 21, pp. 601-611 (1986).	
		Nemeroff, C. et al., "Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims", <i>Arch. Gen. Psychiatry</i> , Vol. 45, pp. 577-579 (1988).	
		Reads, R. et al., "Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients", <i>Clinical Neuroendocrinology</i> , Vol. 60, pp. 436-444 (1994).	
		Boutillier, A. et al., "Corticotropin-Releasing Hormone Stimulates Proopiomelanocortin Transcription by cFos-Dependent and -Independent Pathways: Characterization of an AP1 Site in Exon 1", <i>Molecular Endocrinology</i> , Vol. 9, No. 6, pp. 745-755 (1995).	
		Boutillier, A. et al., "The Protooncogene c-fos Is Induced by Corticotropin-Releasing Factor and Stimulates Proopiomelanocortin Gene Transcription in Pituitary Cells", <i>Molecular Endocrinology</i> , Vol. 5, No. 9, pp. 1301-1310 (1991).	
		Mazzuchelli, C. et al., "The inducible cyclic adenosine monophosphate early repressor (ICER) in the pituitary intermediate lobe: role in the stress response", <i>Molecular and Cellular Endocrinology</i> , Vol. 155, pp. 101-113 (1999).	
		Oliveira-dos-Santos, A. et al., "Regulation of T cell activation, anxiety, and male aggression by RGS2", <i>Proc Natl Acad Sci USA</i> , Vol. 97, No. 22, pp. 12272-12277 (2000).	
		Tse, A. et al., "Voltage-gated Ca ²⁺ channels and intracellular Ca ²⁺ release regulate exocytosis in identified rat corticotrophs", <i>Journal of Physiology</i> , Vol. 528.1, pp. 79-90 (2000).	
		Beinfeld, M.C., "CCK mRNA Expression, Pro-CCK Processing, and Regulated Secretion of Immunoreactive CCK Peptides by Rat Insulinoma (RIN 5F) and Mouse Pituitary Tumor (AIT-20) Cells in Culture", <i>Neuropeptides</i> , Vol. 22, pp. 213-217 (1992).	
		Coskun, T. et al., "Pathways mediating CRF-induced inhibition of gastric emptying in rats", <i>Regulatory Peptides</i> , Vol. 69, pp. 113-120 (1996).	
		Kellner, M. et al., "Behavioral and Endocrine Response to Cholecystokinin Tetrapeptide in Patients with Posttraumatic Stress Disorder", <i>Society of Biological Psychiatry</i> , Vol. 47, pp. 107-111 (2000).	

Examiner Signature	/Christine Saoud/	Date Considered	04/14/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number: † Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

PTO/SB/A (08-00)
 Approved for use through 10/31/2002. OMB 0951-0031
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/532,740
Filing Date	April 26, 2005
First Named Inventor	Pieter Johan Peeters
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	PRD-2008-USPCT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Geraciotti, T. et al. "Intra- and Inter-Individual Correlations Between Cholecystokinin and Corticotropin-Releasing Hormone Concentrations in Human Cerebrospinal Fluid", Depression and Anxiety, Vol. 10, pp. 77-80 (1999).	
		Calogero, A. et al. "Effects of Cholecystokinin Octapeptide on the Hypothalamic-Pituitary-Adrenal Axis Function and on Vasopressin, Prolactin and Growth Hormone Release in Humans", Neuroendocrinology, Vol. 58, pp. 71-76 (1993).	
		Biro, E. et al. "Role of Endogenous Corticotropin-Releasing Factor in Mediation of Neuroendocrine and Behavioral Responses to Cholecystokinin Octapeptide Sulfate Ester in Rats", Neuroendocrinology, Vol. 57, pp. 340-345 (1993).	
		Kamilaris, T. et al. "Cholecystokinin-Octapeptide Stimulates Hypothalamic-Pituitary-Adrenal Function in Rats: Role of Corticotropin-Releasing Hormone", Vol. 130, No. 4, pp. 1764-1774 (1992).	
		Shan, J. et al. "Intracerebroventricular Adrenomedullin Stimulates the Hypothalamic-Pituitary-Adrenal Axis, the Sympathetic Nervous System and Production of Hypothalamic Nitric Oxide", Journal of Neuroendocrinology, Vol. 13, pp. 975-984 (2001).	
		Martinez, V. et al. "Central Action of Adrenomedullin to Inhibit Gastric Emptying in Rats", Endocrinology, Vol. 138, No. 9, pp. 3749-3755 (1997).	
		Parkeas, D. et al. "ACTH-Suppressive and Vasodilator Action of Adrenomedullin in Conscious Sheep", Journal of Neuroendocrinology, Vol. 7, pp. 923-929 (1995).	
		Samson, W. et al. "A Novel Vasoactive Peptide, Adrenomedullin Inhibits Pituitary Adrenocorticotropin Release", Endocrinology, Vol. 136, No. 5, pp. 2349-2352 (1995).	
		Letizia, C. et al. "Circulating Adrenomedullin is Increased in Patients With Corticotropin-Dependent Cushing's Syndrome Due to Pituitary Adenoma", Metabolism, Vol. 49, No. 6, pp. 760-763 (2000).	
		Wouters, L. et al. "Graphical Exploration of Gene Expression Data: A Comparative Study of Three Multivariate Methods", Biometrics, Vol. 59, pp. 1131-1139 (2003).	
		Parkeas, D. et al. "Corticotropin-Releasing Factor Activates c-fos, NGF-B, and Corticotropin-Releasing Factor Gene Expression within the Paraventricular Nucleus of the Rat Hypothalamus", Molecular Endocrinology, Vol. 7, No. 10, pp. 1357-1367 (1993).	
		Database EMBL (Online), Accession No. BC030729; XP002384779 (2002).	
		Database EMBL (Online), Accession No. A1255353; XP002384780 (1998).	
		Database EMBL (Online), Accession No. MMU67187; XP002384781 (1997).	
		Database Trembl (Online), Accession No. Q9QX17; XP002241804 (2000).	
		Tewari, M. et al., "Lymphoid Expression and Regulation of A20, an Inhibitor of Programmed Cell Death", Journal of Immunology, Vol. 154, No. 4, pp. 1699-1706 (1995).	

Examiner Signature	/Christine Saoud/	Date Considered	04/14/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./